SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

iBio, Inc. (IBIO) (CIK 0001420720)
Date: June 18, 2025 · CIK: 0001420720 · Accession: 0000000000-25-006428

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-288000

Date
June 18, 2025
Author
Division of
Form
UPLOAD
Company
iBio, Inc. (IBIO) (CIK 0001420720)

Letter

Re: iBio, Inc. Registration Statement on Form S-3 Filed June 13, 2025 File No. 333-288000 Dear Martin Brenner:

June 18, 2025

Martin Brenner Chief Executive Officer iBio, Inc. 11750 Sorrento Valley Road, Suite 200 San Diego, CA 92121

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Lauren Hamill at 303-844-1008 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Melissa Murawsky

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 June 18, 2025

Martin Brenner
Chief Executive Officer
iBio, Inc.
11750 Sorrento Valley Road, Suite 200
San Diego, CA 92121

 Re: iBio, Inc.
 Registration Statement on Form S-3
 Filed June 13, 2025
 File No. 333-288000
Dear Martin Brenner:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Lauren Hamill at 303-844-1008 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Melissa Murawsky
</TEXT>
</DOCUMENT>